CeMines takes lung cancer diagnostic:
This article was originally published in Clinica
Executive Summary
CeMines has CE-marked for sale in Europe its molecular blood test kit for helping doctors diagnose lung cancer. The CellCorrect KvA-40 LAb kit, the first product from the firm's CellCorrect family of tests to reach the market, is accurate, simple-to-use and cost-effective, claims the Golden, Colorado-based company. It detects disease-related antibodies in the blood using CeMines' Molecular FingerPrinting bioinformatics technology, which evaluates cancer-related antibody patterns and their relevant statistical profiles; the test is able to differentiate and characterise the cancer. Its data are presented in an easy-to-read "score format" that does not require subjective interpretation by physicians. In the US, CeMines filed a 510(k) marketing application for the test in May last year.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.